CA2663730A1 - Assessing the risk of disease progression for a patient with rheumatoid arthritis - Google Patents

Assessing the risk of disease progression for a patient with rheumatoid arthritis Download PDF

Info

Publication number
CA2663730A1
CA2663730A1 CA002663730A CA2663730A CA2663730A1 CA 2663730 A1 CA2663730 A1 CA 2663730A1 CA 002663730 A CA002663730 A CA 002663730A CA 2663730 A CA2663730 A CA 2663730A CA 2663730 A1 CA2663730 A1 CA 2663730A1
Authority
CA
Canada
Prior art keywords
marker
patient
score
markers
disease progression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002663730A
Other languages
English (en)
French (fr)
Inventor
Johann Karl
Veit Grunert
Wolfgang Rollinger
Norbert Wild
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2663730A1 publication Critical patent/CA2663730A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002663730A 2006-09-29 2007-09-25 Assessing the risk of disease progression for a patient with rheumatoid arthritis Abandoned CA2663730A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06020645.5 2006-09-29
EP06020645 2006-09-29
EP06021887.2 2006-10-19
EP06021887 2006-10-19
PCT/EP2007/008313 WO2008037420A1 (en) 2006-09-29 2007-09-25 Assessing the risk of disease progression for a patient with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CA2663730A1 true CA2663730A1 (en) 2008-04-03

Family

ID=38859738

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002663730A Abandoned CA2663730A1 (en) 2006-09-29 2007-09-25 Assessing the risk of disease progression for a patient with rheumatoid arthritis

Country Status (6)

Country Link
US (1) US8058013B2 (enExample)
EP (1) EP2074428B1 (enExample)
JP (1) JP2010506147A (enExample)
CA (1) CA2663730A1 (enExample)
ES (1) ES2545688T3 (enExample)
WO (1) WO2008037420A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010038104A1 (en) * 2008-10-03 2010-04-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event.
CA2777800C (en) 2009-10-15 2019-11-12 Crescendo Bioscience Biomarkers and methods for measuring and monitoring inflammatory disease activity
US20130246097A1 (en) * 2010-03-17 2013-09-19 Howard M. Kenney Medical Information Systems and Medical Data Processing Methods
WO2011129382A1 (en) * 2010-04-16 2011-10-20 Abbott Japan Co. Ltd. Methods and reagents for diagnosing rheumatoid arthritis
WO2012012183A2 (en) * 2010-06-30 2012-01-26 New York University Quantifying local inflammatory activity and its use to predict disease progression and tailor treatments
JP5924659B2 (ja) * 2010-10-14 2016-05-25 国立大学法人 長崎大学 免疫複合体の網羅的解析方法および新規関節リウマチバイオマーカー
WO2012061821A1 (en) * 2010-11-06 2012-05-10 Crescendo Bioscience Biomarkers for predicting progressive joint damage
US11531033B2 (en) * 2013-03-15 2022-12-20 Exagen Inc. Methods for treating and diagnosing systemic lupus erythematosus
JP2015061592A (ja) * 2013-08-21 2015-04-02 コニカミノルタ株式会社 超音波診断装置、超音波画像処理方法およびコンピュータ読み取り可能な非一時的な記録媒体
CA2943821A1 (en) 2014-04-02 2015-10-08 Crescendo Bioscience Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity
JP2017523437A (ja) 2014-06-10 2017-08-17 クレッシェンド バイオサイエンス インコーポレイテッド 体軸性脊椎関節炎の疾患活動性を測定およびモニタリングするためのバイオマーカーおよび方法
WO2017058999A2 (en) 2015-09-29 2017-04-06 Crescendo Bioscience Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal
JP6830105B2 (ja) 2015-09-29 2021-02-17 クレッシェンド バイオサイエンス インコーポレイテッド 乾癬性関節炎の疾患活動性を評価するためのバイオマーカーおよび方法
GB201603571D0 (en) * 2016-03-01 2016-04-13 Univ Warwick Markers for skeletal disorders
EP4052044A1 (en) * 2019-10-30 2022-09-07 CD Diagnostics, Inc. Biomarkers of early osteoarthritis
CN114089632B (zh) * 2021-11-15 2023-08-18 陕西师范大学 基于模糊逻辑的风湿免疫疾病特征识别方法及系统

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9105893D0 (en) 1991-03-20 1991-05-08 Orion Yhtymae Oy Bone resorption assay based on a peptide liberated during collagen degradation
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ATE199185T1 (de) 1994-10-17 2001-02-15 Osteometer Biotech As Einschätzung der fragmentierungsmuster von kollagen in körperflüssigkeiten und diagnose von mit dem kollagenmetabolismus zusammenhängenden störungen
FR2752842B1 (fr) 1996-08-30 1998-11-06 Biomerieux Sa Antigenes derives des filaggrines et leur utilisation pour le diagnostic de la polyarthrite rhumatoide
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
JP2002512939A (ja) 1997-11-28 2002-05-08 イノジェネティックス・ナムローゼ・フェンノートシャップ 診断および治療のためのツールとしての、リューマチ性関節炎の血清により認識されるシトルリン含有合成ペプチド
FR2773157B1 (fr) 1997-12-30 2001-10-05 Bio Merieux Epitopes peptidiques reconnus par des auto-anticorps antifilaggrine presents dans le serum des patients atteints de polyarthrite rhumatoide
NZ504683A (en) * 1998-01-09 2002-06-28 Pfizer Amide derivatives and pharmaceutical compositions thereof and their use as matrix metalloprotease inhibitors
EP1240180A2 (en) 1999-12-21 2002-09-18 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
NL1019540C2 (nl) 2001-12-11 2003-07-01 Stichting Tech Wetenschapp Werkwijze voor het detecteren van auto-antilichamen van patienten die lijden aan reumatoïde artritis, peptide en assaykit.
EP1721163B1 (en) * 2004-02-27 2015-04-29 Roche Diagnostics GmbH Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
US20060063162A1 (en) * 2004-09-23 2006-03-23 Deng David X Biological marker for inflammation
WO2006098401A1 (ja) * 2005-03-16 2006-09-21 The University Of Tokushima 関節リウマチ罹患リスクの測定方法
CN101443357A (zh) * 2005-08-12 2009-05-27 先灵公司 Mcp1融合物

Also Published As

Publication number Publication date
ES2545688T3 (es) 2015-09-15
US20090270272A1 (en) 2009-10-29
JP2010506147A (ja) 2010-02-25
US8058013B2 (en) 2011-11-15
EP2074428B1 (en) 2015-07-01
WO2008037420A1 (en) 2008-04-03
EP2074428A1 (en) 2009-07-01

Similar Documents

Publication Publication Date Title
US8058013B2 (en) Assessing risk of disease progression in rheumatoid arthritis patients
Visser Early diagnosis of rheumatoid arthritis
Hurnakova et al. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis
US8062907B2 (en) Method to assess the severity of rheumatoid arthritis by measuring anti-CCP and serum amyloid A
US20070148704A1 (en) Anti-CCPand antinuclear antibodies in diagnosis of rheumatoid arthritis
CA2546312C (en) Method of assessing rheumatoid arthritis by measuring anti-ccp and interleukin 6
CN101523218B (zh) 评估类风湿性关节炎患者疾病进展的风险
CA2552425C (en) Method of assessing rheumatoid arthritis by measuring rheumatoid factor and interleukin-6
CN104105967B (zh) 生腱蛋白c及其在类风湿关节炎的用途
HK1136628B (en) Assessing the risk of disease progression for a patient with rheumatoid arthritis
HK1136628A (en) Assessing the risk of disease progression for a patient with rheumatoid arthritis
Yasin et al. Extensive study of CCN4, VCAM-1, MMP-3, and GM-CSF as reliable markers for disease activity in rheumatoid arthritis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20180403